What is TVTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.64B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TVTX?

P/E (TTM) is n/a and 52-week range is $22.59 to $68.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TVTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TVTX?

The company profile lists revenue (TTM) near $596M, net income (TTM) near -$4.38B, EPS (TTM) near -$0.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Travere Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 94.3M shares outstanding, ISIN US89422G1076 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Travere Therapeutics, Inc.

$TVTX

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Employees

497

Website

travere.com/

IPO

2003-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US89422G1076

Headquarters

San Diego, California, US

Shares outstanding

94.3M

NAICS sector

Manufacturing

Institutional ownership

110.79%

Browse other companiesFree AI scores and summaries for more stocks